Predictive Oncology Stock Today
| POAI Stock | USD 1.34 0.17 11.26% |
Performance0 of 100
| Odds Of DistressOver 85
|
Predictive Oncology is trading at 1.34 as of the 1st of May 2024. This is a -11.26 percent decrease since the beginning of the trading day. The stock's open price was 1.51. Predictive Oncology has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Predictive Oncology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 1st of April 2024 and ending today, the 1st of May 2024. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 29th of January 2018 | Category Healthcare | Classification Health Care |
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence primarily in the United States. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. The company has 4.06 M outstanding shares of which 12.98 K shares are at this time shorted by private and institutional investors with about 0.44 trading days to cover. More on Predictive Oncology
Moving together with Predictive Stock
| 0.65 | AHG | Akso Health Group | PairCorr |
| 0.73 | CVS | CVS Health Corp | PairCorr |
| 0.76 | SSY | SunLink Health Systems | PairCorr |
| 0.76 | TFX | Teleflex Incorporated Earnings Call This Week | PairCorr |
Moving against Predictive Stock
| 0.89 | GCTK | GlucoTrack | PairCorr |
| 0.8 | SNDA | Sonida Senior Living | PairCorr |
| 0.74 | TNDM | Tandem Diabetes Care | PairCorr |
| 0.65 | JYNT | Joint Corp Financial Report 2nd of May 2024 | PairCorr |
| 0.43 | TLIS | Talis Biomedical Corp | PairCorr |
Predictive Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Predictive Oncology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Predictive Oncology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Predictive Oncology report their recommendations after researching Predictive Oncology's financial statements, talking to executives and customers, or listening in on Predictive Oncology's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Predictive Oncology. The Predictive consensus assessment is calculated by taking the average forecast from all of the analysts covering Predictive Oncology. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key measurements obtained from Predictive Oncology's financial statements, Predictive Oncology is not in a good financial situation at this time. It has a very high probability of going through financial hardship in June. Financial strength of Predictive Oncology is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Predictive Oncology's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Predictive Oncology's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Predictive Oncology's financial leverage. It provides some insight into what part of Predictive Oncology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Predictive Oncology (POAI) is traded on NASDAQ Exchange in USA. It is located in 2915 Commers Drive, Eagan, MN, United States, 55121 and employs 34 people. Predictive Oncology is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.44 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Predictive Oncology's market, we take the total number of its shares issued and multiply it by Predictive Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Predictive Oncology conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 4.06 M outstanding shares of which 12.98 K shares are at this time shorted by private and institutional investors with about 0.44 trading days to cover.
Predictive Oncology currently holds about 25.39 M in cash with (13.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32.
Check Predictive Oncology Probability Of Bankruptcy
Ownership AllocationPredictive Oncology holds 3.55 pct. of its outstanding shares held by insiders and 9.1 pct. owned by third-party entities.
Check Predictive Ownership Details
Predictive Stock Price Odds Analysis
Coming from a normal probability distribution, the odds of Predictive Oncology jumping above the current price in 90 days from now is over 95.68%. The Predictive Oncology probability density function shows the probability of Predictive Oncology stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.6687 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Predictive Oncology will likely underperform. Additionally, predictive Oncology has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Predictive Oncology to move above the current price in 90 days from now is over 95.68 (This Predictive Oncology probability density function shows the probability of Predictive Stock to fall within a particular range of prices over 90 days) .
Predictive Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Predictive Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Predictive Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Predictive Oncology's value.| Instituion | Recorded On | Shares | |
| Blackrock Inc | 2023-12-31 | 152 | |
| Wells Fargo & Co | 2023-12-31 | 31.0 | |
| Jpmorgan Chase & Co | 2023-12-31 | 6.0 | |
| Cwm, Llc Duplicate | 2023-09-30 | 5.0 | |
| Bank Of America Corp | 2023-12-31 | 4.0 | |
| Cornerstone Planning Group Llc | 2023-12-31 | 1.0 | |
| Susquehanna International Group, Llp | 2023-12-31 | 0.0 | |
| Vanguard Group Inc | 2023-12-31 | 140.6 K | |
| Raymond James & Associates | 2023-12-31 | 120.8 K | |
| Geode Capital Management, Llc | 2023-12-31 | 37.5 K | |
| Rb Capital Management, Llc | 2023-12-31 | 20.8 K |
Predictive Oncology Historical Income Statement
Predictive Oncology Income Statement is one of the three primary financial statements used for reporting Predictive's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Predictive Oncology revenue and expense. Predictive Oncology Income Statement primarily focuses on the company's revenues and expenses during a particular period.
As of now, Predictive Oncology's Interest Expense is increasing as compared to previous years. The Predictive Oncology's current Gross Profit is estimated to increase to about 523.2 K, while Depreciation And Amortization is projected to decrease to under 702.4 K. View More FundamentalsPredictive Stock Against Markets
Picking the right benchmark for Predictive Oncology stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Predictive Oncology stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Predictive Oncology is critical whether you are bullish or bearish towards Predictive Oncology at a given time. Please also check how Predictive Oncology's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Predictive Oncology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Fundamental Analysis Now
Fundamental AnalysisView fundamental data based on most recent published financial statements |
| All Next | Launch Module |
Predictive Oncology Corporate Management
Elected by the shareholders, the Predictive Oncology's board of directors comprises two types of representatives: Predictive Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Predictive. The board's role is to monitor Predictive Oncology's management team and ensure that shareholders' interests are well served. Predictive Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Predictive Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joshua MBA | Interim Officer | Profile | |
| BS BSc | VP RD | Profile | |
| Pamela MBA | Chief Officer | Profile | |
| Raymond Vennare | CEO Chairman | Profile | |
| DSc OD | VP Operations | Profile | |
| Julia Kirshner | Chief Officer | Profile |
How to buy Predictive Stock?
Before investing in Predictive Oncology, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Predictive Oncology. To buy Predictive Oncology stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Predictive Oncology. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Predictive Oncology stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Predictive Oncology stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Predictive Oncology stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Predictive Oncology, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Predictive Stock please use our How to Invest in Predictive Oncology guide.
Already Invested in Predictive Oncology?
The danger of trading Predictive Oncology is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Predictive Oncology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Predictive Oncology. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Predictive Oncology is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.Note that the Predictive Oncology information on this page should be used as a complementary analysis to other Predictive Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Predictive Stock analysis
When running Predictive Oncology's price analysis, check to measure Predictive Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Predictive Oncology is operating at the current time. Most of Predictive Oncology's value examination focuses on studying past and present price action to predict the probability of Predictive Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Predictive Oncology's price. Additionally, you may evaluate how the addition of Predictive Oncology to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |
Is Predictive Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.48) | Revenue Per Share 0.443 | Quarterly Revenue Growth (0.08) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.